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Conflict of interest and the Society for Vascular
Surgery
Bruce M. Elliott, MD, FACS, Charleston, SC
Specialty medical societies such as Society for Vascular Surgery (SVS) are instrumental in the development and
dissemination of medical knowledge through scientific presentations, publication of rigorously peer-reviewed writings,
awarding competitive research and training grants, and the provision of high-quality continuing medical education
(CME). It is vital that in these roles the SVS remain in fact and in perception completely free of all influence and bias from
industry. While independence from bias has always been necessary, the increasing focus by governmental agencies,
industry organizations, and society has made it important for the SVS to address this issue in a formal way. In June 2010,
the SVS Board of Directors approved a set of guidelines specifically designed to address management of conflict of interest
among its members and its leaders. These guidelines, included in this article, were based on currently available
information and policies put forth by legislative bodies, academicmedical centers, industry groups, and other professional
medical societies, and were designed to safeguard against abuse while maintaining valuable collaboration between
vascular surgeons and their industry partners. The guidelines are included in this article. ( J Vasc Surg 2011;54:3S-11S.)
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iMedical and specialty medical societies have historically
been viewed as the appropriate forums for the dissemina-
tion of scientifically-based medical knowledge and its appli-
cations, often resulting in significant advancements in med-
ical care. The Society for Vascular Surgery (SVS) has a
fiduciary responsibility to our patients and the public as
advocates for their safe outcomes and treatment innova-
tions that are data driven, as well as remaining a credible
voice for political advocacy. Today, our Society, as aremany
other medical societies, is instrumental in the development
and dissemination of medical knowledge through scientific
presentations, publication of rigorously peer-reviewed
writings, awarding competitive research and training
grants, and the provision of high-quality continuing med-
ical education.
Central to all of these missions, though, is a foundation
of credibility, accountability, and trust. It is the Society’s
responsibility to recognize any threat, real or perceived, to
the trust conferred upon it. Today, there is a heightened
awareness of opportunities for inappropriate financial rela-
tionships between industry, pharma, physicians, universi-
ties, and medical societies. Yet conversely, many extraordi-
nary advances in medical knowledge and technology have
taken place because of appropriately structured industry/
physician collaborations. Many nationally prominent au-
thorities and physician-leaders have achieved their reputa-
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doi:10.1016/j.jvs.2011.04.066ions because of these successful relationships. Obviously,
n outright prohibition of these relationships potentially
isks stifling the innovative environment necessary for sci-
ntific and medical advancement. Conversely, thinly-veiled
aid consultant arrangements created to expand device
mplantations or a drug’s market share epitomize the type
f unethical behavior that seriously threatens the credibility
f our Society and our profession.
It is the responsibility of both the SVS’s leadership and
embership to recognize when situations arise that may
hreaten the Society’s credibility, either real or perceived.
ecognizing any threat, it is obligated to actively and
ransparently act to manage these threats, either through
utright prohibition of the activity, individual or group
ecusal from leadership responsibilities, or structuring a
elationship that is fully transparent and at “arm’s length,”
evoid of any influence on the Society’s decisions. Our
atients, our membership, and the public rightfully expect
nd demand this.1,2
ODE FOR INTERACTIONS WITH
OMPANIES
The Board of Directors of the SVS approved the “So-
iety for Vascular Surgery Guidelines for Interaction with
ompanies” in March, 20113 (Attachment 1). These
uidelines are consistent with the guidelines promulgated
y the Council of Medical Specialty Societies (CMSS).2
riefly, the SVS Guidelines for Interaction with Companies
equires independence from company influence in educa-
ional, programmatic, scientific, and advocacy activities. It
reates a high level group (Conflict of Interest [COI]
ommittee) to oversee andmonitor industrial interactions.
t prohibits any direct or “substantial” financial relation-
hip, defined as a compensated relationship that should
enerate an IRS Form W-2, 1099, or equivalent income
eport, between a Society officer or their spouse, editor of
ts journal, the chairmen of the Practice Guideline Com-
ittee, Documents Oversight Committee, andQuality and
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office and for 1 year following. Excluded from this prohi-
bition are Institutional Review Board (IRB)-approved re-
search grants, which are administered through the individ-
ual’s institution, that do not result in direct payments to the
individual.
A separate, but inter-related document, “Managing
Conflict of Interest: Policy on Managing Conflict of Inter-
est for the Leadership of the Society for Vascular Sur-
gery,”4,5 originally published in 2000, was recently revised
and is attached (Attachment 2). This document provides
the framework for disclosure, recusal, conflicts that should
be disclosed, and how disclosures are managed.
CODE OF ETHICS FOR SVS MEMBERS
The SVS has a separate statement of ethics for its
members, “Code of Ethics for SVS Members,”6 affirmed
by the SVS Board in January, 2010 (Attachment 3). Em-
bedded within the Code of Ethics are several principles
pertinent to conflict of interest. They include prohibition of
receipt of direct payments from industry for travel, lodging,
or personal expenses to attend scientific or educational
conferences or meetings. Faculty for conferences are al-
lowed to accept reimbursement for reasonable expenses.
Unrestricted educational grants may be accepted by an
institution, provided the company does not select the re-
cipients or the speakers. Members may only accept modest
gifts from companies that benefit patient care or serve an
educational function and have a fair market value of less
than $100. Finally, charitable donations should be made to
charitable organizations or foundations, rather than to
individual members.
The SVS Executive Committee convened a retreat in
January 2009 to discuss the changing environment con-
cerning industry relationships. Following this retreat, a task
force on industry support, chaired by the Society’s imme-
diate past president, Patrick Clagett, MD, was formed. The
task force members, O. William Brown, MD, Frank
LoGerfo, MD, Lewis Schwartz, MD, and Cynthia K. Shor-
tell, MD, prepared a draft document approved by the SVS
Board in January 2010, the “SVS Guidelines for Interac-
tion with Companies.”3 President Sidawy appointed the
SVS Conflict of Interest Committee in 2010. The SVS
Conflict of Interest Committee members include Bruce
Elliott, MD, Chair, Patrick Clagett, MD, Frank LeGerfo,
MD, Richard Neville, MD, and Linda Reilly, MD. This
committee has proposed multiple revisions to the three
policies described in this presentation to the SVS board
during its first year. It has implemented a disclosure process
for the SVS officers, board members, committee chairs and
members; reviewed approximately 200 of these disclosures;
and made management recommendations to the SVS Ex-
ecutive Committee concerning them. It is prepared to
advise any SVS leader, committee member, or SVSmember
on potential conflicts or concerns and to hear all sides of any
issues brought forward, ultimately advising the SVS Exec-
utive Committee of its recommendations. mTTACHMENT 1
uidelines for SVS interaction with companies
Preamble. There are two central tenets expressed in
he Hippocratic Oath that are relevant to the relationship
etween the SVS and industry. The first is that the welfare
f patients comes first, and that the practice of medicine
schews external influences that might be harmful to pa-
ients or interrupt the “covenant of trust” between physi-
ian and patient. The second is that physicians should strive
o maintain life-long learning and keep abreast of advances
n medicine. While these apply to individual physician’s
ractice of medicine, they are also relevant to corporate
eliberations of professional medical societies such as the
VS. Adherence and fidelity to these principles engender
espect, trust, and autonomy for the individual practitioner
nd for professional medical societies.
Through its many activities, the SVS makes distinctive
ontributions to the advancement of vascular care. The
VS’s educational venues (Vascular Annual Meeting
VAM], Journal of Vascular Surgery [JVS], textbooks and
ontinuing medical education [CME] courses) inform
embers of new and established diagnostic and treatment
rocedures. SVS Practice Guidelines and Reporting Stan-
ards establish evidence-based, optimal patient care. By
ngaging in outreach to medical students, residents, and
ellows, the SVS ensures a future supply of completely
rained vascular practitioners. The SVS also engages in
ublic outreach though VascularWeb and other venues to
romote vascular health and education. A public agenda is
lso manifest in health policy initiatives that advocate for
he particular interests of SVS members, patients, and for
hat we believe is best for society as a whole.
The development of these and other SVS activities
eflect a depth of expertise and maturation of authority that
ave significant influence inside and outside of medicine.
hysicians from other specialties and the general public will
ncreasingly rely on SVS evidence-based information and
ecommendations in the treatment of vascular disease.
herefore, any compromise of scientific integrity or un-
ualified commitment to patient care must be anticipated
nd avoided.
The relationship between professional medical societies
nd industry, specifically the pharmaceutical and medical de-
ice industries, has come under increasing scrutiny. The chief
oncern is that industry, through its financial support of med-
cal societies, may influence educational and other society
ctivities in amanner that would compromise clinical decision
aking. As a consequence, this might lead to adverse delivery
f optimal health care and undermine the reputation of the
rofession.
On the other hand, a healthy relationship between pro-
essional medical societies and industry can promote optimal
nd excellent health care. Collaboration can lead to research,
nnovation, new treatments, and expanded educational activ-
ties. As an example, industry support of CME meetings
educes costs to individual attendees and therebymakes CME
ore accessible. For rapidly evolving technologies and devices
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essential. Training on newly-approved devices may be man-
dated by the Food andDrugAdministration, and professional
medical societies have an obligation to their membership to
partner with industry in facilitating training.
Currently, the SVS receives approximately 20% of its
annual revenue from industry support. This comes from un-
restricted grants for the VAM, income derived from the VAM
exhibits, and unrestricted grants to support SVS research
projects. Thus, there exists a significant financial relationship
between the SVS and industry that is subject to external
scrutiny. In order to clarify and promote a healthy and ethical
relationship with industry, the SVS ad hoc Task Force on
Industry Support developed the following guidelines. The
principles underlying the guidelines include transparency, full
disclosure of all individual and SVS financial relationships with
industry, and themaintenance of appropriate barriers between
industry transactions and programmatic decisions.
Guidelines.
I. General principles
A. SVS will develop all programs, products, services,
and advocacy positions independent of company
influence.
B. SVS will separate its fundraising efforts and busi-
ness transactions from programmatic decisions.
C. SVS will use written agreements with companies
for grants, sponsorship, charitable donations, and
business transactions that will specify what the
funds are for, the amount given, and the separate
roles of the company and the Society.
D. These guidelines will apply to SVS and to its
charitable foundation, the American Vascular As-
sociation.
II. Transparency
A. The SVS will disclose company support for SVS
activities to include company name, category of
support (eg, educational grant, research support,
and charitable donations), length of support, and
dollar amount. This will be updated annually.
There will be no restriction in the amount of
aggregate company support (eg, 10%, 25%, etc.
of the SVS operating budget). However, the per-
cent of SVS budget supported by companies will
be disclosed.
B. The SVS will disclose relationships that officers,
members of the Board of Directors, Council
chairs, committee chairs, and SVS staff have with
companies.
C. The SVS will make its conflict-of-interest policies
known to its members and the public and will
make individual disclosures available on request.
III. Educational grants and continuing medical educa-
tion
A. SVS will comply with Accreditation Council for
Continuing Medical Education (ACCME) Stan-
dards for Commercial Support for all SVS-
sponsored CME activities.B. SVS will retain control over the use of educa-
tional grants and implement safeguards de-
signed to ensure that educational programs are
non-promotional and free from commercial in-
fluence and bias. Industry educational grants for
the VAM, for example, are unrestricted grants for
the entire meeting, not for individual sessions.
C. Individuals with control over SVS CME content,
including SVS staff, will comply with established
SVS ACCME procedures to identify and resolve
all conflicts of interest prior to the CME activity
being delivered to learners. The new SVSConflict
of Interest Committee (see below) will serve as
the final arbitrator for any unresolved conflicts of
interest.
D. SVS will limit support opportunities to general
topics that are not product-specific.
E. SVS will make efforts to achieve a diversified
portfolio of company support for CME pro-
grams.
F. Satellite Symposia at VAM.
1. Satellite Symposia are not part of the
ACCME-accredited portion of the VAM, and
SVS will take appropriate steps to make this
known to VAM attendees (disclaimers in Pro-
gram Book and other VAM literature).
2. SVS will direct companies to announce or
publish in symposia material that their sympo-
sia are not part of the ACCME-accredited
portion of the VAM.
3. Satellite Symposia will not conflict with sched-
uled VAM events.
4. SVS officers and Board of Director members
may attend but will not participate in Satellite
Symposia as speakers, moderators, or other
significant participants, as this gives the ap-
pearance that SVS is endorsing company
product(s).
IV. Company logos will not be placed on items such as
lanyards, tote bags, highlighters, flashdrives, or other
company-branded items.
V. Exhibits
A. SVS will have written policies governing the na-
ture of exhibits and the conduct of exhibitors.
SVS policies will require exhibitors to comply
with applicable laws, regulations, and guidance.
SVS policies can place limits on exhibits and
exhibitor conduct to ensure that the tone of the
exhibit hall is professional in nature.
B. SVS will only permit exhibitor gifts to attendees
that are educational and modest in value. Noned-
ucational, branded items are prohibited.
C. SVS will ensure that educational sessions for
which SVS CME credits (such as poster sessions)
are granted are physically separated from com-
pany exhibits.
D. SVS officers and other SVS leaders (eg, members
of the board of directors, JVS Editors, Council,
JOURNAL OF VASCULAR SURGERY
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in company promotional/marketing events held
in the exhibit hall.
VI. Society publications
A. SVS print and electronic publications, including
VascularWeb, will have editorial independence
from their advertisers.
B. SVS publications will require editors and review-
ers to disclose financial and other relationships
with companies.
C. SVS publications will require authors and trial site
directors to disclose financial and other relation-
ships with companies.
D. SVS will have written policies that set standards
for advertisements and/or sponsorship in its print
and electronic publications.
VII. Endorsements and licensing
A. SVS will adopt written policies that set standards
for licensing intended to prevent misuse, unin-
tended use, andmodification of licensedmaterial.
B. SVS will prohibit use of licensed materials and
trademarks to imply Society endorsement of
company products and services.
C. SVS will not engage in company product endorse-
ment.
VIII. Research grants
A. SVS will not permit companies to select or influ-
ence the selection of recipients of grants awarded
by the SVS. SVS will appoint independent com-
mittees to select recipients of grants supported by
company funds based on peer review of grant
applications.
B. Companies will not be allowed to choose topics
for research grants.
C. SVS will not name research grants for companies.
D. SVS will not require grant recipients to meet with
companies that supported the SVS-awarded
grant. In fact, such interactions should be
avoided.
E. SVS will not permit companies who support SVS-
awarded grants to receive intellectual property
rights or royalties arising out of the grant-funded
research.
F. SVS will not permit companies who support SVS-
awarded research grants to control or influence
publications that arise from the grant-funded re-
search.
G. SVS will not permit device companies to be in-
volved inmanagement of any registries, including
decisions to sell or otherwise disclose or publish
registry data.
IX. Educational grants for students, residents, and fel-
lows
A. Company funds for scholarships or other funds to
support medical students, residents, and fellows
to attend educational events may be permitted,
provided that selection of recipients is made by
SVS or by the recipient’s academic institution.B. Educational grants will not bear a company name
or logo.
C. SVS will not require grant recipients to meet with
companies that supported the SVS-awarded
grant. In fact, such interactions should be
avoided.
X. Clinical practice guidelines and performance/
outcomes measures
A. SVS will not permit company support of the
development of clinical practice guidelines, per-
formance measures, or outcomes measures.
B. Panel members responsible for developing guide-
lines or measures will disclose all potential con-
flicts of interest relevant to the subject matter of
the guidelines or measures and will disclose all
financial or uncompensated relationships with
companies.
C. In the event that the Chair of the guidelines or
measures committee has a conflict of interest in
the form of having a direct and substantial finan-
cial relationship with a company, a co-chair free of
conflict should be appointed.
D. Complete disclosure information from panel
members will be published with the guidelines or
measures.
E. Panel members and staff are not permitted to
discuss guidelines or measures development with
company employees or representatives. Compa-
nies will not be permitted to review guidelines or
measures in draft form.
F. SVS will not permit direct company support for
the original printing, publication, or distribution
of guidelines or measures.
XI. Charitable donations from companies
A. SVS or the American Vascular Association (AVA)
will control the use of donations from companies
consistent with the SVS and AVA mission and
strategic plans.
B. SVS and AVA will decline donations where the
donor expects to influence programs or advocacy
positions.
C. Donations targeted for broad categories are ac-
ceptable, consistent with the SVS or AVAmission
(eg, research, education, patient information, in-
ternational programs, etc.).
D. SVS and AVA will adhere to applicable tax rules
and legal standards for acceptance of donations.
E. SVS and AVA will engage in appropriate recog-
nition of donors. Donor recognition is a funda-
mental part of fundraising and should be con-
ducted with appropriate limitations.
1. Donors may be recognized in print materials,
in private or public ceremonies, and with ban-
ners and other visual displays.
2. Donor recognition should be provided in a
manner that does not imply donor influence
over SVS programs or advocacy positions.
XJOURNAL OF VASCULAR SURGERY
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A. SVSmay accept sponsorship for Society programs
outside CME or research, but the sponsored pro-
grams must be consistent with the Society’s stra-
tegic plan or mission.
B. SVS will make efforts to seek multiple sources for
outside funding for sponsored programs.
C. SVS will engage in appropriate recognition of
program sponsors.
D. Company logos on noneducational company-
branded items (eg, tote bags, lanyards, note-
books, highlighters, etc.) will not be permitted as
is consistent with generally accepted standards for
ethical interactions defined in the Pharmaceutical
Research and Manufacturers of America (PhRMA)
and AdvaMed Codes.
E. SVS activities and programs seeking company
support will be made known to the Conflict of
Interest Committee who will advise the SVS Ex-
ecutive Committee on the appropriateness of
company support for such activities.
F. SVS will not accept company support for the
following activities: Society Board of Directors,
council and committee meetings; Society man-
agement meetings, and other meetings con-
cerned with governance, planning, and oversight
of the Society; published materials related to the
Society’s membership recruitment, identity, or
governance.
XIII. Society leadership
A. No SVS officer may have direct financial relation-
ships with companies during his or her term of
service.
1. Officers include president, president-elect,
vice-president, secretary, and treasurer.
2. A direct financial relationship is a compen-
sated relationship held by an individual that
should generate an IRS Form W-2, 1099 or
equivalent income report.
3. Officers have 6months to terminate any direct
financial relationships after election to office,
or before the first meeting of the Board of
Directors, whichever is first.
4. SVS officers may accept research support as
long as grant money is paid to the institution
where the research is conducted (eg, academic
medical center), not to the individual. Re-
search support, uncompensated services, and
other permitted relationships should never-
theless be disclosed to the Society.
5. Exceptions to any of the above may be ap-
pealed to the SVS Conflict of Interest Com-
mittee (Section XIV) who will make recom-
mendations to the Board of Directors.
B. All individuals serving in a volunteer or staff ca-
pacity for SVS will complete the SVS Conflict of
Interest Form on an annual basis and prior toassuming their responsibilities. The Form will be
reviewed by the SVS Conflict of Interest Com-
mittee.
C. SVS staff are prohibited from having any financial
relationships with companies.
D. At the beginning of major SVS leadership meetings
(meetings of the Board of Directors, Councils, stra-
tegic planning retreats, etc.), the President/Chair
will review the Conflict of Interest Forms of
attendees. During discussions involving compa-
nies where a potential conflict of interest with an
attendee exists, the individual should recuse
themselves.
IV. Guideline implementation
A. SVS will appoint a Conflict of Interest Commit-
tee.
B. Members of this Committee will themselves be
free of conflicts of interest and have no ties to
companies.
C. Responsibilities of this Committee include the
following:
1. Review annually all Conflict of Interest Forms of
SVS officers, members of the board of directors,
council members, committee chairs, practice
guideline and performance/outcomes mea-
sures committee members, JVS editors, staff,
and any other SVS members in circumstances
subject to company influence that could jeop-
ardize the Society’s integrity.
2. Individuals with control over SVS CME con-
tent, including SVS staff, must comply with
SVS procedures to identify and resolve all
conflicts of interest prior to the CME activity
being delivered to learners. The Conflict of
Interest Committee will serve as the final ar-
bitrator for any unresolved conflicts of inter-
est.
3. In situations where there is information that is
at variance with disclosure information pro-
vided an individual, the Committee may re-
quest clarification from the individual and/or
company.
4. In situations where there is a significant con-
flict of interest that may impair the integrity of
the SVS, the Committee will notify and advise
the SVS Executive Committee.
5. In accordance with ACCME guidelines, an
individual who fails to disclose relevant finan-
cial relationships will be disqualified from be-
ing a member of any committee with CME
planning responsibility or oversight, including
SVS Board, councils, and committees.
D. The Committee will review these Guidelines an-
nually or as often as necessary and update them to
be consistent with ethical guidelines promulgated
by other major organizations such as the Ameri-
can Medical Association, American College of
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Societies (CMSS), American Association of Med-
ical Colleges, Institute of Medicine, AdvaMed,
PhRMA, and others.
ATTACHMENT 2
Policy on managing conflict of interest for the
leadership of the Society for Vascular Surgery
The purpose of this document is to provide guidelines
for the management of possible conflicts of interest for the
Society for Vascular Surgery (SVS) leadership. In this doc-
ument, the “Leadership of the SVS” includes the individu-
als serving on the Board, Executive Committee of the
Board, Councils, committees, task forces, employees, or
any other position of leadership.
We review the background principles and suggest ap-
proaches that will be helpful in recognizing, avoiding, and
dealing with situations that may represent a conflict of
interest.
Background
The importance of a statement of ethical standard.
Issues of conflict of interest have assumed greater focus in
maintaining trust. The overall goal of establishing stan-
dards for managing possible conflicts of interest is to main-
tain the public confidence in the Society and to protect the
stature of the Society by ensuring that the integrity of the
decision-making processes by the Leadership of the SVS is
not biased by financial or professional interests. It is appro-
priate to consider how to minimize the influence of real or
perceived self-interest.
Definition. Competition of interest is a circumstance
or situation that is present when an individual’s primary
responsibility of providing unbiased and impartial deci-
sions, judgments, or opinions on behalf of the SVS might
be influenced by a secondary factor. There is nothing
wrong with having secondary interests, and indeed, it is
often desirable to select individuals for appointments who
have broad interests or relationships. However, problems
arise if the secondary interests (eg, the potential for per-
sonal financial profit, professional gain, or academic gain)
influence or appear to influence the primary responsibility.
Individuals may be influenced by financial relation-
ships, responsibilities on other Boards or in other organi-
zations, or personal bias. For pragmatic reasons, financial
conflicts of interest are often considered to be the most
important problem, but other responsibilities or personal
biases are equally important.
Is conflict of interest present? Although it may not
be possible to precisely identify conflict of interest, the
following factors are important to consider in judging if
conflict of interest is present: (1) it exists with respect to a
specific circumstance or situation; (2) conflict of interest
exists in relationship to a role and the duties and moral
requirements attached to the role; (3) the greater the
potential for personal gain, the greater the concern about ehe significance of the conflict of interest; and (4) the
reater the potential harm, the greater the concern.
Because absolute rules are not possible, an appropriate
est of potential conflict is to evaluate whether a decision or
ctions of the SVS would be considered to be trustworthy
nd credible if the potential conflict were made known.
Seriousness of the conflict. The severity of a conflict
epends on multiple factors. The factors include (1) the
mportance of the individual’s primary role (eg, the fidu-
iary responsibility of providing unbiased advice to the
VS); (2) the likelihood that the individual’s obligation,
ctions, views, judgment, or decisions for the SVS will be
nfluenced by secondary factors; and (3) the seriousness of
he harm that might result if undue influence is present.
Existing approaches to providing a solution. Law
nd ethics interact and usually are mutually reinforcing;
hey are briefly discussed below.
Bioethics. Modern bioethics is based on the principles
f beneficence (to do good), nonmalfeasance (to minimize
arm), justice, and patient autonomy.
With regards to the actions of the Leadership of the
VS, the principle of justice is the standard against which
ur efforts in dealing with conflicts of interest can be best be
easured.
Law and guidelines. It is the responsibility of the
oard of the SVS to be certain that mechanisms are in place
o create and sustain an ethical environment in the SVS as
n organization and within the Board. This would include
s a minimum a statement of ethical standards, effective
mplementation and application of the standards, and reg-
lar monitoring, communication, and reassessment of eth-
cal issues.
The conduct of security traders, agents, lawyers in the
awyer/client relationship, and others is governed by a
arge body of legal opinions and disciplinary rulings by
ourts and other bodies. In law, the principles of conflict of
nterest grew out of fiduciary law, specifically the law of
rusts where trustees are required to act solely in the inter-
sts of the beneficiary. Analogous common law principles
ould include those related to fiduciary duty, informed
onsent, negligence, bad faith, kickbacks, and fraud. In
any states, statutes apply to the duties of directors and
fficers of nonprofit corporations. For example, under the
llinois corporation statute governing the SVS, a transac-
ion directly between a corporation and one of its directors
s permissible, as long as the substance of the transaction is
air to the corporation at the time it is approved. With
espect to the process for establishing fairness, a key ele-
ent under the Illinois statue is whether the material facts
f the transaction and the nature of the director’s separate
nterest are disclosed to the decision-making body before
he decision is made. Another key element is that the
ecision was approved by a majority of the disinterested
irectors.
In serving the SVS, the Leaders have certain fiduciary
bligations: specifically, they must (1) act in the best inter-
st of the SVS, (2) avoid conflict of interest that might bias
4n
(
t
o
d
b
a
L
f
w
i
t
d
E
n
c
p
T
d
p
d
e
T
fl
r
o
r
p
s
o
m
f
d
p
d
p
m
i
w
i
q
T
B
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 18S Elliott 9Stheir decisions, and (3) not compete with the SVS with
regards to corporate opportunities.
Policy for dealing with conflict of interest or com-
mitment.
Principle. The Leadership of the SVS shall avoid con-
flict of interest between the well-being of the SVS and their
own personal financial gain or other responsibilities. This
shall apply in fulfilling their obligations, making decisions,
and expressing their views on behalf of the SVS.
Two approaches are suggested.
Voluntary recusal. The SVS encourages each individ-
ual to exercise character and good judgment to be aware
that self-interests may unintentionally bias his or her deci-
sions or actions on certain issues and to voluntarily with-
draw himself or herself from discussion of these issues. At
each Board, Council, or Committee meeting, the chair will
remind the members of the importance of declaring any
potential conflict of interest and note that they must recuse
themselves from discussion on the relevant agenda item if a
conflict exists.
Disclosure – principles regarding disclosure. The fol-
lowing principles (regulations) are not a substitute for
openness and integrity but will be useful in managing
complex situations that might pose a conflict of interest.
With regard to the principles (regulations), the following
comments are of note.
First, in the development of an approach to prevent a
circumstance where there is the perception of a conflict of
interest in relationship to an individual carrying out his or
her SVS duties, it must be recognized that there may be
disagreement on the baseline standard of behavior beyond
which it would be considered unsatisfactory. Second, be-
cause of the complexity of the ethical situation, categorical
rules are not possible: only principles can be established,
and they must be applied with discretion. Third, the rules
are based on the assumption that disclosure of potential
conflicts will help to avoid potential problems. Note that
disclosure does not necessarily provide the solution for
addressing the potential problem. If the conflict is signifi-
cant because the individual has substantial secondary inter-
ests, the solutions include either abstention from involve-
ment or divestiture of the secondary interests.
Financial interests that should be disclosed. Because of
the influence of their positions, the Leadership of the SVS
must be particularly sensitive to the issue of actual or
perceived conflict of interest. Financial conflict of interest
may be present if an individual (or spouse) has any of the
following relationships with biomedical companies, device
manufacturers, or pharmaceutical companies:
1. Officer, board member, trustee, owner, or employee of
a company.
2. Direct owner of stock, stock options, or bonds of a
company.
3. Paid consultancy, scientific advisory committee mem-
bership, or lecturer for a company, investigator for a
company, including holding research grants from thecompany that are paid to the individual rather than the
individual’s institution.
. Personal income from a patent
Other conflicts that should be disclosed. In practice,
onfinancial conflicting interests may be equally important
eg, loyalty to more than one organization). Responsibili-
ies to other organizations (eg, other vascular society or
rganization) may represent a conflict of interest related to
ecisions made on behalf of the SVS. Significant personal
iases should be acknowledged and disclosed.
Procedure for avoiding conflict of interest, disclosure,
nd actions. On an annual basis, each member of the
eadership of the SVS will complete a conflict of interest
orm and submit it to the executive director. The form
ill ask individuals to list their possible conflicts of
nterest. During the year, the individual should volun-
arily update the information as necessary. The compiled
isclosures will be available to the chairs of the Board,
xecutive Committee, Councils, and Committees on a
eed-to-know basis.
At each Board, Council, or Committee meeting, the
hair will request that all members disclose if they have any
otential conflict of interest with items on the agenda.
hose with a conflict of interest will not participate in the
iscussion or vote on the matter. It will usually be appro-
riate for the individual to leave the room during the
iscussion and the vote or recuse themselves from a confer-
nce call if the meeting is conducted through that method.
he minutes will reflect the action taken.
If there is a question on an individual’s potential con-
ict of interest, the chair will make the decision as to
ecusal. If the chair is perceived to have a potential conflict
f interest in relationship to an agenda item, the decision on
ecusal will be made by a majority vote of all other members
resent. Members should refrain from accepting SVS re-
ponsibilities if they have or are likely to have a financial or
ther relationship that might impair or appear to impair the
ember’s objectivity.
Sanctions and appeal. If an individual willfully fails to
ully disclose the information requested, he or she will be
isqualified from participation in decisions of the SVS for a
eriod of not 12 months.
If an appeal is lodged, regarding a conflict-of-interest
ecision, a committee consisting of the three most recent
ast presidents (the chair will be decided by mutual agree-
ent by the three individuals), that have no conflict of
nterest regarding the issue or the individual in question
ill meet to address and suggest solutions to the conflict of
nterest and will answer an individual’s complaints or re-
uests for appeal on a decision related to conflict of interest.
his committee’s decision may be appealed to the SVS
oard.
Wayne Johnston, MD
Anton N. Sidawy, MD
Affirmed by SVS Board of Directors, January 2010.
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Code of ethics for SVS members
General statement of purpose. This document is
intended to serve as a guide for members of the Society for
Vascular Surgery (SVS) in their medical, social, and profes-
sional relationships in the practice of vascular surgery. This
code is a statement of ideals, commitments, and responsi-
bilities of SVS members to their patients, other health
professionals, society, and themselves. It will be considered
as one of the criteria used to evaluate qualifications for
membership by applicants and to evaluate a member’s
maintenance of good professional standing in the SVS.
Ethics as related to the provision of vascular care. An
SVS member shall serve as the patient’s advocate to ensure
that the most appropriate care is provided to the patient.
An SVSmember shall not participate in any activity that
is not in the best interest of the patient.
An SVS member shall practice within the limitations of
his or her privileges, which reflect his or her competencies
and expertise.
An SVSmember shall not publicize or represent himself
or herself in any untruthful, misleading, or deceptive man-
ner to patients, colleagues, other health care professionals,
or the public.
An SVS member shall be actively involved in continu-
ing medical education in order to remain current on new
medical information related to vascular interventions.
Should an SVS member become dependent on alcohol
or drugs or otherwise become impaired, he or she should
accept treatment and recommendations of the treating
physician(s) and the recommendations of his or her hospital
committee, local medical society committee, and/or ACS
guidelines for evaluating and assisting impaired physicians.
Ethics of relationships between health care profes-
sionals. An SVS member shall strive to achieve and main-
tain professional and courteous relationships with his or her
colleagues and other health care professionals.
If an SVS member has reason to believe that another
SVS member is incompetent, he/she shall bring this situa-
tion to that person’s attention and advise the appropriate
professional committee of his or her hospital or regional
medical society.
An SVS member shall not practice medicine while
impaired by alcohol, drugs, or physical or mental disability.
The vascular surgeon who experiences substance abuse
problems or who is physically or emotionally impaired
should seek appropriate assistance to address these prob-
lems and limit his or her practice until the impairment no
longer affects the quality of patient care.
An SVS member shall respect the rights of colleagues
and of other health professionals.
An SVS member shall only receive compensation for
services provided within the rules as defined in the relevant
laws.
The division of income among members of a formally
organized group is appropriate and can be based on the
value of the services performed by each member and/or tther contributions to the group, as agreed to in advance by
he group members.
An SVS member who transfers care of a patient to
nother health care provider, either by his or her own
ecommendation or at the request of the patient or pa-
ient’s family, shall cooperate fully with the health care
rovider who receives the transferred patient.
An SVS member shall be actively involved in the edu-
ational process of other physicians and health care provid-
rs as circumstances permit. An SVS member shall help his
r her medical colleagues maintain a high level of perfor-
ance and integrity in the practice of medicine.
Ethics related to the patient and patient’s
amily. An SVS member and the patient and/or patient’s
amily, when appropriate, shall be involved in dialogue so
he joint medical decision-making process will be in keep-
ng with the patient’s philosophy and wishes and their
dvanced Directive for health care.
Explanation of the nature and risk of an operation to
he patient or to the patient’s representative is essential.
An SVS member shall maintain the privacy and confi-
entiality of patient information. Patient health informa-
ion, protected under the Health Insurance Portability and
ccountability Act (HIPAA) and other laws, shall be re-
pected except in those circumstances where the law re-
uires disclosure.
Sexual misconduct on the part of an SVS member is an
buse of professional power and a violation of patient trust
nd is unethical.
An SVS member shall collaborate with other health
are professions and advocate for the terminally ill patient
o allow dignity and provide relief of pain and suffering.
he lawful wishes of the competent patient shall be
espected.
Ethics as related to the legal profession. An SVS
ember shall respect the confidentiality of the doctor–
atient relationship as defined by HIPAA regulation.
As an expert witness, an SVS member shall thoroughly
repare by reviewing the relevant facts so that he or she can,
o the best of his or her ability, provide the court with
ccurate and documented opinions on the matters at hand.
An SVS member shall follow the SVS “Guidelines for
estimony by Vascular Surgeons Serving as Expert Wit-
esses in Litigation.”
Responsibilities of the SVS member to govern-
ent. An SVS member shall always abide by the law of the
and, but support changes in those laws that are in the best
nterests of the patient and medical practice.
An SVS member shall cooperate with and deal honestly
ith governmental agencies involving those areas of
ealth care in which he or she is a participant, but will
reserve patient confidentiality.
Ethics related to the physician and insurance, com-
ensation, and reimbursement agencies. An SVS mem-
er shall be honest in financial dealings with patients,
nsurance companies, and health care financing agencies,
nd shall provide accurate, complete, and timely informa-
ion to these entities.
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completely to requests for medical reports from private and
governmental agencies involved in reimbursement and com-
pensation formedically related serviceswith the consent of the
patient or the patient’s agent, or as otherwise provided by
the law.
Financial and administrative constraints imposed by
managed care may create disincentives to treatment that
have been recommended by the vascular surgeon as being
in the patient’s best interest. Any pertinent constraints or
incentives should be disclosed to the patient.
Ethics related to relationships with industry. An
SVSmember should not accept direct payment from indus-
try (defined as individuals or organizations with a commer-
cial interest in the field of vascular surgery or related
health care issues) for the costs of travel, lodging, or other
personal expenses to attend scientific or educational con-
ferences or meetings. Faculty at such conferences or edu-
cational meetings can accept reasonable honoraria and
reimbursement of reasonable expenses. Unrestricted ed-
ucational grants to a training institution or society can be
disbursed to cover expenses of individuals, but the medical
technology companymust not select the recipients or select
the speakers. Residents and fellows in training can accept
travel grants if the grants are awarded to a third party who
should select the recipients based on established criteria.
An SVS member should not accept cash or any gifts of
substantial value directly from industry. Any gift must be
modest, benefit patient care or serve a genuine educational
function, and have a fair market value of less than $100.
An SVS member can accept donations for charitable
purposes such as supporting independent medical research
for the advancement of medical science, patient education,
public education, or the sponsorship of educational
courses.
An SVS member can accept remuneration for consult-
ing services providing that the payment is based on fair
market value compensation and is entered into only where
a legitimate need and purpose is identified in advance, and
selection of the consultant should be based solely on the
consultant’s qualifications and expertise.
An SVS member should not enter into any relationship
with industry that might influence his or her primary re-
sponsibility for care of the individual patient. SWhen there is the potential for conflict of interest, an
VS member must disclose to colleagues and patients any
nancial relationships that he or she has with industry.
Ethics as related to patients and research. An SVS
ember involved in human research shall respect the rights
f the participants, obtain approval from an appropriate
nstitutional human review committee, and fully inform the
articipants before proceeding with any treatment or
esearch.
An SVS member may perform innovative procedures in
onnection with rigorous validation trials to ensure that
ew operative procedures are safe and effective only if:
● Each prospective study is evaluated and approved by an
appropriate federal and/or local institutional oversight
committee;
● Patients are fully informed of the nature of the study,
risks of the new procedure, and alternative treatment
options.
Ethics related to community and world affairs. SVS
embers, in addition to providing care to the individual
atient, have a responsibility to be involved in community
nd humanitarian activities, especially those matters affect-
ng health.
Approved by SVS Board of Directors, June 2004
Affirmed by SVS Board of Directors, January 2010
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